# A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

> **NCT00673556** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 195 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** alefacept
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00673556
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2014-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673556, "A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00673556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*